115 search results for: chronic inflammation

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
On Demand
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
On Demand
IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Presentation highlights from the ADVENT symposium on smell loss and nasal congestion in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.

ADVENT Forum 2025 Event Page
Awareness Day
4
April
2025
Awareness Day
ADVENT Forum 2025 Event Page

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

Expert Interview with Dr Jason Hawkes
Dermatology
Expert Interview with Dr Jason Hawkes
expert video

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.

View more
EADV 2025
Congress
17
September
2025
Congress
EADV 2025 Congress

ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more
ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Congress
5
April
2024
Congress
ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.